Search

Your search keyword '"Noordzij, W"' showing total 4 results
Start Over Author "Noordzij, W" Journal amyloid the international journal of experimental and clinical investigation the official journal of the international society of amyloidosis
4 results on '"Noordzij, W"'

1. Additional diagnostic value of SPECT/CT to planar Iodine-123 labeled serum amyloid P component scintigraphy in a patient with pulmonary nodular amyloidosis.

Author

Noordzij W, Glaudemans AW, van Rheenen RW, Dierckx RA, Slart RH, and Hazenberg BP

Subjects
Female, Humans, Middle Aged, Radiography, Serum Amyloid P-Component, Amyloidosis diagnostic imaging, Iodine Radioisotopes, Lung Diseases diagnostic imaging, Radionuclide Imaging methods, Tomography, Emission-Computed, Single-Photon methods
Published
2014
Full Text
View/download PDF

2. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.

Author

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, and Hazenberg BP

Subjects
Adult, Aged, Aged, 80 and over, Bone and Bones diagnostic imaging, Cardiomyopathies pathology, Early Diagnosis, Female, Heart Ventricles diagnostic imaging, Heart Ventricles pathology, Humans, Male, Middle Aged, Radionuclide Imaging, Technetium Tc 99m Medronate pharmacokinetics, Tissue Distribution, Amyloid Neuropathies, Familial diagnostic imaging, Cardiomyopathies diagnostic imaging, Radiopharmaceuticals pharmacokinetics, Technetium Tc 99m Medronate analogs & derivatives
Abstract

Objective: To assess the usefulness of bone scintigraphy with (99m)Technetium-hydroxymethylene diphosphonate ((99m)Tc-HDP) for the detection of cardiac involvement in a group of patients with ATTR amyloidosis in different phases of disease, to relate the findings to echocardiography, ECG and cardiac biomarkers, and to evaluate different bone scintigraphic techniques and calculation methods for quantification of the cardiac uptake and for correlation with echocardiographic features and cardiac biomarkers., Methods: Forty-one patients underwent clinical examinations, echocardiography, ECG, measurement of cardiac biomarkers and bone scintigraphy (planar imaging and SPECT-CT) and were subsequently subdivided into three groups: (1) carriers of an amyloidogenic TTR mutation, n = 11, (2) proven ATTR amyloidosis without echocardiographically-defined (mean wall thickness >12 mm) cardiac amyloidosis (AC), n = 19, and (3) ATTR amyloidosis with echocardiographically-defined cardiac amyloidosis, n = 11. Planar and SPECT-CT images were analyzed visually according to a routine scoring system (grade 0-3) and semi-quantitatively by heart-to-whole body (H/WB) and heart-to-skull (H/S) ratio on planar images and by a left ventricle-blood pool ratio on SPECT-CT images., Results: All patients with ATTR and echocardiographically-defined AC and none of the carriers showed high cardiac uptake on bone scintigraphy. Furthermore, 8 out of 19 patients with ATTR without echocardiographically-defined AC showed high cardiac uptake. Highest correlations were found between H/S ratio on planar bone scintigraphy with troponin T (r = 0.76, p < 0.0001) and H/WB ratio with left ventricular mass index (r = 0.73, p < 0.0001)., Conclusions: Bone scintigraphy with (99m)Tc-HDP may detect cardiac involvement in patients with ATTR amyloidosis prior to echocardiographic evidence of cardiac involvement. Cardiac uptake on bone scintigraphy correlates with severity of cardiac involvement using echocardiography, ECG and cardiac biomarkers. Visual grading and calculation of H/S ratio on planar imaging are the preferred methods to assess cardiac uptake.

Published
2014
Full Text
View/download PDF

4. Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis.

Author

Noordzij W, Glaudemans AW, Slart RH, Dierckx RA, and Hazenberg BP

Subjects
Aged, Amyloid metabolism, Amyloid Neuropathies, Familial diagnostic imaging, Amyloid Neuropathies, Familial pathology, Female, Heart diagnostic imaging, Humans, Iodine Radioisotopes, Male, Radiography, Radiopharmaceuticals, Technetium, Tomography, Emission-Computed, Single-Photon, Amyloid Neuropathies, Familial diagnosis, Nuclear Medicine methods
Abstract

Histological proof remains the gold standard for the diagnosis of amyloidosis. Nuclear medicine imaging techniques are able to determine the amyloid load in the body. Currently, the best imaging modality is (123)I-SAP scintigraphy. This modality has high sensitivity for detecting amyloid deposits in all amyloid subtypes. Involvement of liver and spleen can be visualized before clinical signs are present. The addition of single photon emission computed tomography improves the differentiation of overlying organs. However, (123)I-SAP is not FDA approved. Its availability is limited to two centres in Europe. Furthermore, it is not suitable for imaging cardiac involvement of amyloidosis, due to movement, blood-pool content and lack of fenestrated endothelial in the myocardium. Phosphate derivates labelled with (99m)Tc, are able to detect calcium compounds in cardiac amyloidosis. Finally, (123)I-MIBG, an analogue of norepinephrine, can detect cardiac sympathetic innervation abnormalities as a consequence of amyloid deposits. Both these last techniques seem to be able to detect cardiac involvement before echocardiographic parameters are present. We illustrate the clinical use of these modalities with two patients with ATTR type amyloidosis.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results